农业百科

Molecular Devices and STEMCELL Technologies said they have a developed a validated automated workflow that can be used with STEMCELL’s IntestiCult™ Plus organoid growth medium for human intestinal organoids culture on the Molecular Devices CellXpress.ai automated cell culture system.

Planted, one of Europe’s leading meat alternative makers, is outperforming the sector in Europe’s leading meat alternative market.

Why it matters: The deal is part of a broader Novartis push to solve one of neurology’s biggest technical problems: getting large therapeutic molecules across the blood-brain barrier. Rather than betting on a single approach, the Swiss pharma is assembling several brain-shuttle technologies that could work with different drug classes.

Why it matters: The deal is another big pharma endorsement of macrocycles as a way to combine some of the target-binding properties of biologics with the convenience of oral drugs. It also gives Orbis its first Big Pharma partnership, less than two years after the company emerged from stealth.

Why it matters: Bispecific antibodies, long concentrated in oncology, are increasingly moving into autoimmune and inflammatory diseases. Roche is already developing several approaches in the field, and the Dualitas deal gives it a way to search much more broadly for new target combinations.

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified candidate treatment targets and potential prognostic markers for high-grade glioma (HGG), an aggressive brain cancer in children, adolescents, and young adults (AYA). The study found that high-grade glioma varies by developmental stage and sex, showing distinct tumor biology and outcomes across patient groups.

AgFunderNews rounds up the most important fundings, mergers, acquisitions, closures, and industry buzz in agtech and foo…

Sartorius and the Ireland-based National Institute for Bioprocessing Research and Training (NIBRT) are partnering to establish a training center for intensified and fully continuous bioprocessing in Dublin. Starting in the fourth quarter of 2026, the center will serve as a hub for practical training and knowledge sharing to help the biopharmaceutical industry adopt intensified, digitalized, and continuous manufacturing processes, according to Sartorius officials.

Robigo Bio has closed a Series A financing round to accelerate the commercial launch of its crop biological products, wh…